Obakulactone reduced joint swelling in rats, Engineering study finds

An experimental plant-derived compound reduced joint swelling and cartilage damage in laboratory rats by targeting fat metabolism pathways, according to findings published in the journal Engineering.

Key Clinical Takeaways:
• Obakulactone (OL), a tetracyclic triterpenoid extracted from Phellodendri cortex, decreased joint inflammation and protected joint tissues in a 21-day animal model study.
• The substance works by promoting the breakdown of the ACOT1 protein via the ubiquitin-proteasome pathway, altering unsaturated fatty acid processing.
• Researchers observed dose-dependent reductions in inflammatory cytokines, including IL-1β, IL-6, IL-17, and TNF-α, along with suppressed CD3+ T cell and CD68+ macrophage infiltration.

Extraction of Obakulactone from Phellodendri Cortex

The investigations center on obakulactone, a naturally occurring tetracyclic triterpenoid defined by a four-ring chemical structure extracted from the bark plant Phellodendri cortex. To test its therapeutic potential, investigators established a rat model of rheumatoid arthritis using complete Freund's adjuvant to provoke a strong inflammatory response. Animals were administered obakulactone daily for 21 days across low (50 mg per kilogram), medium (100 mg per kilogram), and high (200 mg per kilogram) weight-adjusted doses.

Rats receiving the treatment demonstrated measurable decreases in joint swelling. Histological examinations showed that the structure of their cartilage and synovium recovered toward normal parameters. The intervention also altered immune organ profiles in the thymus and spleen while lowering systemic rheumatoid arthritis blood markers, including rheumatoid factor, anti-cyclic citrullinated peptide antibodies, C-reactive protein, and matrix metalloproteinase-3.

Cellular Pathways of Unsaturated Fatty Acid Metabolism

Advanced analytical methods—including metabolomics, MALDI mass spectrometry imaging, and proteomics—revealed that obakulactone corrects abnormalities in unsaturated fatty acid processing. Specifically, the compound regulated molecules such as arachidonic acid, linoleic acid, and alpha-linolenic acid. By targeting these lipids, the substance reduced the production of downstream inflammatory signals associated with joint destruction.

Cellular assays identified acyl coenzyme A thioesterase 1 (ACOT1) as a direct molecular target for the compound. Microscale thermophoresis and surface plasmon resonance produced dissociation constants of 6.18 and 6.34 micromoles per liter, confirming physical binding between obakulactone and ACOT1. The compound then facilitated the destruction of ACOT1 via the cellular ubiquitin-proteasome system.

Suppression of Fibroblast Proliferation and Signaling Cascades

In experiments involving rheumatoid arthritis synovial fibroblasts, obakulactone inhibited excessive cell growth and stimulated apoptosis, the controlled elimination of damaged cells. The degradation of ACOT1 subsequently lowered levels of stearoyl-CoA desaturase-1, an enzyme regulating unsaturated fatty acid production.

These molecular changes suppressed two major cellular signaling networks: Janus kinase-signal transducer and activator of transcription (JAK-STAT) and phosphoinositide 3-kinase-protein kinase B (PI3K-AKT). By interrupting these communication pathways, the plant compound mitigated inflammation and tissue fibrosis in the synovial lining. Researchers noted that while current pharmaceutical options manage symptoms and slow disease progression, adverse side effects and variable patient responses show why new molecular targets like ACOT1 are needed.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.